G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis

Andrew M. Evens*, Jeffrey Cilley, Taylor Ortiz, Mrinal Gounder, Nanjiang Hou, Alfred Rademaker, Sarah Miyata, Kara Catsaros, Connie Augustyniak, Charles L. Bennett, Martin S. Tallman, Daina Variakojis, Jane N. Winter, Leo I. Gordon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Fingerprint

Dive into the research topics of 'G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science